Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H1 2015

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H1 2015', provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Vaginal Atrophy (Atrophic Vaginitis) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Vaginal Atrophy (Atrophic Vaginitis) Overview 7

Therapeutics Development 8

Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis)-Overview 8

Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis)-Comparative Analysis 9

Vaginal Atrophy (Atrophic Vaginitis)-Therapeutics under Development by Companies 10

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Vaginal Atrophy (Atrophic Vaginitis)-Products under Development by Companies 14

Vaginal Atrophy (Atrophic Vaginitis)-Companies Involved in Therapeutics Development 15

Actavis plc 15

EndoCeutics, Inc. 16

Foamix Pharmaceuticals Ltd. 17

MediGene AG 18

Pantarhei Bioscience BV 19

Peptonic medical AB 20

RestorGenex Corporation 21

TherapeuticsMD Inc. 22

Vaginal Atrophy (Atrophic Vaginitis)-Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Mechanism of Action 26

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

esterol-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

estradiol hemihydrate-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

oxytocin-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

prasterone-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

RES-102-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

sinecatechins-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

TX-004HR-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

WC-3011-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Vaginal Atrophy (Atrophic Vaginitis)-Recent Pipeline Updates 44

Vaginal Atrophy (Atrophic Vaginitis)-Dormant Projects 46

Vaginal Atrophy (Atrophic Vaginitis)-Product Development Milestones 47

Featured News & Press Releases 47

Mar 09, 2015: Physicians Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap 47

Feb 20, 2015: Survey Shows Postmenopausal Women with VVA Reported Improved Satisfaction and Quality of Life with VagiCap Investigational Local Estrogen Treatment 47

Oct 28, 2014: First patients included in Peptonic Medical AB's clinical phase 2b study 48

Oct 15, 2014: TherapeuticsMD Announces Oral Presentation of Positive Phase 2 and Bioavailability Data on TX-004HR (VagiCap) 49

Sep 08, 2014: PEPTONIC Medical gets approvals to start the next clinical study 49

Jul 04, 2014: PEPTONIC Medical Progress Towards Next Clinical Study 50

Apr 07, 2014: Therapeutics MD Reports Positive Results of Rabbit Irritation Study for Its Estradiol Vaginal Capsule VagiCap (TX 004-HR) for Treatment of Vulvar Vaginal Atrophy 50

Jan 28, 2014: TherapeuticsMD Reports Positive PK Study Results for Its Estradiol Vaginal Capsule VagiCap (TX 12-004-HR) for Treatment of Vulvar Vaginal Atrophy 51

Oct 22, 2013: TherapeuticsMD Phase 1 Pilot Study Shows TX-12-004-HR Estradiol VagiCap Improves Conditions of Vulvar and Vaginal Atrophy 51

Aug 12, 2013: TherapeuticsMD commences Phase I study of vulvar and vaginal atrophy candidate 52

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2015 8

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Comparative Analysis by Late Stage Development, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Actavis plc, H1 2015 15

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by EndoCeutics, Inc., H1 2015 16

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 17

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by MediGene AG, H1 2015 18

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Pantarhei Bioscience BV, H1 2015 19

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Peptonic medical AB, H1 2015 20

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by RestorGenex Corporation, H1 2015 21

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by TherapeuticsMD Inc., H1 2015 22

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Stage and Target, H1 2015 25

Number of Products by Stage and Mechanism of Action, H1 2015 27

Number of Products by Stage and Route of Administration, H1 2015 29

Number of Products by Stage and Molecule Type, H1 2015 31

Vaginal Atrophy (Atrophic Vaginitis) Therapeutics-Recent Pipeline Updates, H1 2015 44

Vaginal Atrophy (Atrophic Vaginitis)-Dormant Projects, H1 2015 46

List of Figures

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2015 8

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis)-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Assessment by Monotherapy Products, H1 2015 23

Number of Products by Top 10 Targets, H1 2015 24

Number of Products by Stage and Top 10 Targets, H1 2015 25

Number of Products by Top 10 Mechanism of Actions, H1 2015 26

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Top 10 Routes of Administration, H1 2015 28

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29

Number of Products by Top 10 Molecule Types, H1 2015 30

Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Actavis plc

EndoCeutics, Inc.

Foamix Pharmaceuticals Ltd.

MediGene AG

Pantarhei Bioscience BV

Peptonic medical AB

RestorGenex Corporation

TherapeuticsMD Inc.

Vaginal Atrophy (Atrophic Vaginitis) Therapeutic Products under Development, Key Players in Vaginal Atrophy (Atrophic Vaginitis) Therapeutics, Vaginal Atrophy (Atrophic Vaginitis) Pipeline Overview, Vaginal Atrophy (Atrophic Vaginitis) Pipeline, Vaginal Atrophy (Atrophic Vaginitis) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com